Home › Trial NCT00720629
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
- Trial IDNCT00720629
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorH. Lee Moffitt Cancer Center and Research Institute
- Enrollment8
- Start date2007-12
- ConditionsGraft Versus Host Disease
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.